Literature DB >> 26920382

Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.

Sandra Thiel1, Annette Langer-Gould2, Milena Rockhoff3, Aiden Haghikia3, Annette Queisser-Wahrendorf4, Ralf Gold3, Kerstin Hellwig5.   

Abstract

BACKGROUND: Available data suggest that pregnancy exposure to interferon-beta might result in lower mean birth weight and preterm birth.
OBJECTIVE: To determine the effect of interferon-beta exposure during pregnancy on pregnancy outcomes in multiple sclerosis patients.
METHODS: We compared the pregnancy outcomes of women exposed to interferon-beta with pregnancies unexposed to disease-modifying therapies. Women were enrolled into the German Multiple Sclerosis and Pregnancy Registry. A standardized questionnaire was administered during pregnancy and postpartum. Detailed information on course of multiple sclerosis and pregnancy, concomitant medications, delivery, and outcome of pregnancy was obtained.
RESULTS: We collected data on 251 pregnancies exposed to interferon-beta and 194 unexposed to disease-modifying therapies. In all, 246 (98.01%) women discontinued interferon-beta treatment during first trimester. No differences regarding mean birth weight (exposed: 3272.28 ± 563.61 g; unexposed: 3267.46 ± 609.81 g), mean birth length (exposed: 50.73 ± 3.30 cm; unexposed: 50.88 ± 3.45 cm), preterm birth (p = 0.187), spontaneous abortion (p = 0.304), and congenital anomalies (p = 0.197) were observed between the two groups.
CONCLUSIONS: Interferon-beta exposure during early pregnancy does not influence the mean birth weight, risk of preterm birth, or other adverse pregnancy outcomes. Our study provides further reassurance that interferon-beta treatment can be safely continued up until women become pregnant.
© The Author(s), 2016.

Entities:  

Keywords:  Multiple sclerosis; disease-modifying therapies; interferon-beta; pregnancy; pregnancy outcomes; safety

Mesh:

Substances:

Year:  2016        PMID: 26920382     DOI: 10.1177/1352458516634872

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  30 in total

1.  Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.

Authors:  Maria Pia Amato; Antonio Bertolotto; Roberto Brunelli; Paola Cavalla; Benedetta Goretti; Maria Giovanna Marrosu; Francesco Patti; Carlo Pozzilli; Leandro Provinciali; Nicola Rizzo; Nicola Strobelt; Gioacchino Tedeschi; Maria Trojano; Giancarlo Comi
Journal:  Neurol Sci       Date:  2017-08-02       Impact factor: 3.307

2.  Intravenous immunoglobulin treatment in multiple sclerosis: A prospective, rater-blinded analysis of relapse rates during pregnancy and the postnatal period.

Authors:  Alexander Winkelmann; Paulus Stefan Rommer; Michael Hecker; Uwe Klaus Zettl
Journal:  CNS Neurosci Ther       Date:  2018-06-01       Impact factor: 5.243

Review 3.  Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Authors:  Joachim Havla; Clemens Warnke; Tobias Derfuss; Ludwig Kappos; Hans-Peter Hartung; Reinhard Hohlfeld
Journal:  Dtsch Arztebl Int       Date:  2016-12-26       Impact factor: 5.594

Review 4.  An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis.

Authors:  Caila Vaughn; Aisha Bushra; Channa Kolb; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

5.  Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.

Authors:  Leticia Berenguer-Ruiz; Juana Gimenez-Martinez; Antonio Palazón-Bru; Angel Perez Sempere
Journal:  J Neurol       Date:  2019-06-29       Impact factor: 4.849

Review 6.  Pregnancy: Effect on Multiple Sclerosis, Treatment Considerations, and Breastfeeding.

Authors:  Rhonda Voskuhl; Callene Momtazee
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

7.  Family Planning Decision Making in People With Multiple Sclerosis.

Authors:  Simona Bonavita; Luigi Lavorgna; Hilary Worton; Susan Russell; Dominic Jack
Journal:  Front Neurol       Date:  2021-04-28       Impact factor: 4.003

8.  SARS-CoV-2 prevalence and maternal-perinatal outcomes among pregnant women admitted for delivery: Experience from COVID-19-dedicated maternity hospital in Jammu, Jammu and Kashmir (India).

Authors:  Puneet Gupta; Surender Kumar; Shashi S Sharma
Journal:  J Med Virol       Date:  2021-05-24       Impact factor: 20.693

9.  Identification and Prioritization of Important Attributes of Disease-Modifying Drugs in Decision Making among Patients with Multiple Sclerosis: A Nominal Group Technique and Best-Worst Scaling.

Authors:  Ingrid E H Kremer; Silvia M A A Evers; Peter J Jongen; Trudy van der Weijden; Ilona van de Kolk; Mickaël Hiligsmann
Journal:  PLoS One       Date:  2016-11-03       Impact factor: 3.240

10.  The road to conception for women with multiple sclerosis.

Authors:  Dessa Sadovnick; Maria Criscuoli; Irene Yee; Robert Carruthers; Alice Schabas; Penelope Smyth
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.